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Abstract 
Background: Recent reports of emergence and spread of artemisinin resistance in the Southeast Asia region, includ-
ing Myanmar, pose a greater threat to malaria control and elimination in India. Whole genome sequencing studies 
have associated mutations in the K13 propeller gene (k13), PF3D7_1343700 with artemisinin resistance both in vitro 
and in vivo. The aim of the present study was to find the k13 gene polymorphisms in Plasmodium falciparum parasites 
from the three sites in the Northeast region of India, bordering Bangladesh and Myanmar.
Methods: A total of 254 samples collected during 2014–2015 from Tripura, Mizoram and Arunachal Pradesh states in 
the Northeast region of India were used to obtain the full-length k13 gene sequences.
Results: Three non-synonymous (NS) mutations: two in the propeller region, namely at codon 446 and 578, were 
observed besides one at codon 189 in the non-propeller region. The treatment outcome was not affected by these 
mutations at any of the sites. In addition, microsatellite variation in the N-terminus of the k13 protein was observed at 
all the study sites.
Conclusion: This is the first study to document the presence of F446I NS mutation in the k13 propeller region from 
Changlang district, Arunachal Pradesh, a site adjoining the Indo-Myanmar border region, where this mutation is 
highly prevalent. In addition, NS mutation A578S has been observed only at Lunglei district, Mizoram, a site bordering 
Bangladesh and K189T mutation with relatively higher frequency in Mizoram and Tripura states. The presence of F446I 
mutation in a region close to the Myanmar border is notable. Considering the spread of anti-malarial drug resistance 
from Southeast Asia to the Northeast region of India in the past, there is an urgent need to undertake systematic 
mapping studies to ascertain the role and extent of this mutation in artemisinin resistance in this region of country.
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Background
Artemisinin resistance has been detected in Thai-Cam-
bodia border, Vietnam and west Myanmar, in Southeast 
Asia (SEA). Delayed parasite clearance was first observed 
in falciparum malaria patients in Cambodia in 2008 [1]. 
Later, the reduced in  vivo susceptibility to artesunate 
was reported from Cambodia in 2009 [2]. Considering 
the spread of anti-malarial resistance from SEA to the 
Northeast (NE) region of India, there is an urgent need to 
monitor the presence of artemisinin resistance in falcipa-
rum malaria in the border areas of the country.
In the NE region, artesunate plus sulfadoxine-
pyrimethamine (AS +  SP) was replaced by artemether-
lumefantrine in 2013 due to high treatment failure with 
AS + SP in falciparum malaria during 2012 [3]. However, 
AS + SP remains the first-line therapy for uncomplicated 
falciparum malaria in the rest of the country [4].
Recently, mutations in the Kelch propeller pro-
tein, encoded by the PF3D7_1343700 gene, have been 
linked to artemisinin resistance, both through in  vitro 
and in  vivo studies [5]. Accordingly, the WHO defi-
nition of suspected artemisinin resistance includes 
cases with the presence of >5% of patients carrying k13 
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resistance  associated single nucleotide polymorphisms 
(SNPs) while for confirmed resistance, the k13 mutants 
should be associated with either persistent parasitaemia 
on day 3 or longer parasite clearance time [6]. k13 pro-
peller SNPs have been investigated in different countries 
to detect the presence of resistant parasites. To date, 
resistance associated multiple mutations in the k13 gene 
have been described in SEA particularly in the Greater 
Mekong region, mainly in propeller region and a few 
novel mutations [5–10].
Mapping of Kelch propeller region across Indian states 
over time has been done in 2014 where four non-syn-
onymous (NS) mutations were detected in the propel-
ler region. Out of these four NS mutations, three were 
from the NE region in the country, and one from Jalpaig-
uri, West Bengal, which connects the NE with the rest 
of India. The four NS mutations did not correlate with 
treatment outcome in the patients except one (G533A) 
from Gomati Tripura, where the outcome was late treat-
ment failure on day 28 [11]. Presence of these four NS 
mutations prompted the focus in the NE region, and the 
k13 gene was sequenced in 254 samples using Sanger 
sequencing method. All mutations observed in the study 
were validated with another PCR and by resequencing 
k13.
Methods
Collection of samples and DNA extraction
Patients were enrolled in therapeutic efficacy studies of 
artemether-lumefantrine in falciparum malaria at three 
study sites located in the NE region of India across inter-
national borders and were followed as per WHO guide-
lines [12]. Out of these study sites, two were located at 
the Indo-Bangladesh and one at Indo-Myanmar border 
(Fig.  1). Directly observed treatment of quality assured 
drugs supplied by the WHO was given. Finger-prick 
blood spots were obtained on Whatman filter paper 
strips (3 mm) from patients on day 0 and were analyzed 
for Kelch mapping.
k13 propeller gene amplification and sequencing analysis
Genomic DNA was extracted from dried blood filter using 
QIAamp® DNA Mini Kit (QIAGEN, Germany), according 
to manufacturer’s instructions. The k13 gene from all sam-
ples were amplified by PCR and the PCR products were 
sequenced (Macrogen, South Korea) as per protocols 
reported previously with modifications [5]. The initial pri-
mary PCR, amplifying the spanning region 53–2126 bases 
of the k13 open-reading frame was carried out using high-
fidelity Phusion PCR master mix (New England Biolabs, 
USA) with primers K13c53-F (5′-TGACGTATGATAGG-
GAATCTGG-3′) and K13c2126-R (5′-CCAAGCTGC-
CATTCATTTGT-3′). Three nested PCR reactions were 
performed (fragment 1, fragment 2 and fragment 3) 
amplifying fragments approximately 650–855 bases of the 





and K13c2126-R (see above) respectively.
Briefly, 25  μl PCR reaction mix contains 12.5  μl Phu-
sion PCR Master Mix (NEB, USA), 1 μl of specific prim-
ers (10  μM stock), and 2  μl of DNA template. Reaction 
conditions consisted of an initial denaturation at 98  °C 
for 30  s followed by 35 cycles of 98  °C for 10  s, 60  °C 
for 20 s and 72 °C for 30 s, and a final extension step for 
10 min at 72 °C. Alignment of DNA sequences was per-
formed using MEGA 6.0 with the k13 sequence of the 
3D7 clone (PF3D7_1343700) retrieved from Plasmo DB 
as the reference.
Results
A total of 254 Plasmodium falciparum samples were col-
lected during therapeutic efficacy studies of artemether-
lumefantrine (AL) in the NE region. The samples 
included in the study were from Arunachal Pradesh 
(n = 85), Tripura (n = 85) and Mizoram (n = 84) states 
(Fig.  1). The k13 gene was successfully PCR amplified 
from all the samples. DNA sequence analysis of k13 from 
the 254 clinical isolates of P. falciparum showed three NS 
and one synonymous mutations (Table  1). In addition, 
variations in the number of microsatellite repeat (ATA) 
were observed in samples from all the study sites corre-
sponding to amino acid positions 137-142 of k13 in 3D7 
parasite (Table 2).
Low frequency of NS mutations in the propeller region 
at codon F446I and A578S was observed with predomi-
nant wild type genotype in the majority of the samples. 
Interestingly, the NS mutations, at amino acid posi-
tion F446I, which corresponds to nucleotide position 
T1336A, was observed in only one sample from Chang-
lang district, Arunachal Pradesh. However, the frequency 
of this mutation in these Indian sites was low (1.2%). The 
other mutation at amino acid A578S in the propeller 
region corresponding to nucleotide position G1732T, has 
also been observed in one sample from Lunglei district, 
Mizoram, a site adjacent to Bangladesh.
Besides these NS mutations, one NS mutation at proxi-
mal end (upstream region) at amino acid K189T corre-
sponding to nucleotide position A566C has also been 
observed at two sites adjoining Bangladesh border. These 
include five samples from Mizoram (5.9%) and three 
(3.5%) from Tripura (Table  1). This mutation has been 
observed at a relatively higher frequency with complete 
absence in samples from Arunachal Pradesh. Out of 
Page 3 of 6Mishra et al. Malar J  (2016) 15:583 
254 samples, only one synonymous mutation at nucleo-
tide position T355C was observed in four samples from 
Tripura and one sample from Mizoram corresponding 
to amino acid position 119L. No synonymous mutations 
have been observed in samples from Arunachal Pradesh. 
Interestingly, the clinical outcome of all of these samples 
with mutations was adequate clinical and parasitologi-
cal (ACPR) response after AL treatment and follow-up 
of 42 days. None of the patients showed delayed parasite 
Fig. 1 Details of study sites in Northeastern region in India
Table 1 Point mutations in  Plasmodium falciparum k13 
gene from Northeast India
An empty cell indicates no point mutation






Lunglei, Mizoram 84 5 1
Gomati, Tripura 85 3
Total 254 8 1 1
Table 2 Site-wise details of microsatellite repeat (N) in k13 
gene
Sites Repeats at microsatellite locus
6 N (wild type) 7 N 8 N 9 N 10 N
AP (85) 52 (61.18%) – 33 (38.82%) – –
MZ (84) 63 (75%) 1 (1.19%) 19 (22.61%) – 1 (1.19%)
SL (85) 53 (62.35%) – 26 (30.58%) 6 (7.06%) –
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clearance or day 3 positivity, an indicator of artemisinin 
resistance in the study areas.
Discussion
For large-scale surveillance, k13 propeller polymor-
phisms have been identified as a useful molecular marker, 
which will help in detecting emerging artemisinin resist-
ance in the region. More than 100 NS mutations, have 
been reported worldwide. In vivo and in vitro data have 
confirmed that the k13 propeller mutations 493H, 539T, 
543T, and 580Y are associated with artemisinin resistance 
while many others are candidate markers for artemisinin 
partial resistance. These include 441L, 446I, 449A, 458Y, 
553L, 561H, 568G, 574L, and 675  V. Distinct alleles 
originating from different independent events of emer-
gence have been observed in Southeast Asia. The Y493H, 
R539T, I543T, and C580Y mutants are highly prevalent 
in Cambodia [5]. Recently, F446I has been reported dur-
ing a therapeutic efficacy study conducted by the Depart-
ment of Medical Research Upper Myanmar and WHO 
at the border between Myanmar and India (Lin, pers. 
comm.) and was further confirmed during a survey con-
ducted in Myanmar [10, 13]. In addition, this mutant has 
been reported from the border between Myanmar and 
China and Myanmar and Thailand [14–16].
Therefore, compared to the Thai-Cambodia region, the 
scenario of k13 mutation is quite different in the regions 
neighbouring northeastern India, which comprises 
Myanmar in the north and Bangladesh in the south. The 
k13 propeller mutations C580Y, M476I, A481 V, N458Y, 
and R539T, which have been shown to be significantly 
associated with day 3 parasitaemia, are only reported 
from the eastern border of Myanmar [14]. The C580Y 
mutation is highly prevalent in Cambodia, Myanmar 
and eastern and western Thailand, while the F446I muta-
tion, which was first reported in 2012, is predominant in 
China-Myanmar border regions as well as in Myanmar 
[8–10, 17].
This is the first report of the k13 polymorphism in 
the propeller region at F446I from Changlang district, 
Arunachal Pradesh, in northeast India. The F446I muta-
tion has been found to be associated with delayed para-
site clearance (PCT) in the adjoining areas of Myanmar, 
as well as in China [18]. However, no correlation of this 
mutation with treatment outcome or delayed PCT was 
observed in the present study. Similarly, F446I has been 
observed to be associated with intermediate rate of para-
site clearance in Upper Myanmar region [19]. Addition-
ally, it is interesting to note that this NS mutation has 
been observed in only single sample from Changlang 
district, Arunachal Pradesh, a site which shares a border 
with Myanmar where this mutation has recently been 
reported at a higher frequency [10, 13]. The frequency 
of this mutation in the Indian site was comparatively 
low (1.2%). The absence of F446I mutation in these sites, 
which are across the Indo-Bangladesh border, is a find-
ing consistent with the absence of k13 mutant parasites 
in Bangladesh and most of west Myanmar, where a low 
prevalence of k13 mutations has been observed [20].
Besides F446I mutation, A578S mutation has also been 
reported from Mizoram, a site in India adjacent to Bang-
ladesh [11]. However, this mutation has been detected at 
a lower frequency and no correlation with treatment out-
come has been observed. In Bangladesh, A578S mutation 
in the k13 propeller region has been reported, however, 
no data on clinical outcome are available [21]. A recent 
study has revealed that A578S mutation is commonly 
observed in Africa and is not associated with artemisinin 
resistance [22]. In addition, one NS mutation at proxi-
mal end (upstream region) K189T has been observed 
from two study sites adjoining the Bangladesh bor-
der at comparatively higher frequency in Mizoram and 
Tripura. A recent study at the China-Myanmar border 
has also shown prevalence of K189T mutation at lower 
frequency (1.6%) compared to a higher prevalence which 
was observed at Dakar, Senegal [18, 20]. Although the 
K189T mutation was observed at a comparatively higher 
frequency in two sites, no correlation with clinical phe-
notype was observed in the samples.
Except F446I mutation, the other mutations K189T and 
A578S in the k13 gene have not been found to be associ-
ated with delayed parasite clearance or confirmed arte-
misinin resistance. The presence in lower frequency as 
background mutations in propeller region or in the prox-
imal end has been documented in the past in SEA and 
in Africa [9]. However, their association with artemisinin 
resistance is still unclear [11]. Although these mutations 
have been reported from northwestern areas of Myanmar 
and China bordering Indian states, their association with 
treatment failure in Indian samples has not been reported 
so far. With no change in the phenotypic characters, it is 
difficult to ascertain whether or not these mutations have 
any role in treatment failure.
As per the published literature, k13 NS propeller region 
mutations are not always associated with artemisinin 
resistance. In fact, such mutants can represent ‘passer-
by’ genotypes: that is, they do not lead to the selection 
of the mutant k13 genotype [23]. Also, it could be sug-
gested that these mutations in k13 arise de novo rather 
than through clonal expansion.
Previously, in northwestern areas of Myanmar bor-
dering India, the majority of mutations in the k13 gene 
included C580Y, F446I and P574L [10]. Of these, the 
highest prevalence was observed for C580Y mutation, 
followed by F446I and P574L respectively. These highly 
prevalent mutations were present in more than 56% of 
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the total number of drug-resistant samples. However, no 
such correlation has been observed in this study.
Miotto et al. [8] observed that parasites with the most 
common k13 mutant alleles (C580Y, I543T, R539T, 
and Y493H) were found in countries in SEA, indicat-
ing that cross-border movement of P. falciparum may 
have already occurred. Since the study sites were located 
near international borders, larger population movement 
across these border areas is possible, which may assist in 
the spread to a larger extent.
Earlier, a few NS mutations at codon G533A, S549Y, 
R561H and A578S have been reported from India, all 
from the Northeast, including one from Jalpaiguri, West 
Bengal [11], which has international borders with Bhu-
tan and Bangladesh in the North and South, respectively. 
Except A578S, no such mutations have been observed in 
this study.
Although AL remains efficacious in the study region 
and these mutations are in low frequency, artemisinin 
combination therapy may pose positive selection on 
the parasites. The rate of transmission and the diversity 
of vector species in the northeastern region may also 
increase selection pressure on parasite strains. There 
is an urgent need for the rational use of anti-malarials 
against P. falciparum strains and for priority on strength-
ening anti-malarial monitoring and surveillance. Detailed 
clinical and laboratory investigations to complement sen-
tinel surveillance, including different tools to monitor 
resistance, are required in this region.
Conclusion
Arunachal Pradesh in India shares a border with Myan-
mar and is prone to anti-malarial drug resistance. Emerg-
ing kelch polymorphisms, particularly F446I mutation 
in low frequency, could be an indication of emerging 
resistance towards artemisinin, however, more detailed 
investigations are needed to confirm this. The two NS 
mutations A578S and K189T observed at relatively 
higher frequency in Mizoram and Tripura could be back-
ground mutations. Thus, the presence of F446I warrants 
the urgent need to undertake systematic mapping stud-
ies to ascertain the role of this mutations in artemisinin 
resistance in this region.
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